

pubs.acs.org/JACS

Argicyclamides A–C Unveil Enzymatic Basis for Guanidine Bisprenylation

Chin-Soon Phan,[#] Kenichi Matsuda,[#] Nandani Balloo, Kei Fujita, Toshiyuki Wakimoto,* and Tatsufumi Okino*

Cite This: J. A	n. Chem. Soc. 2021, 143, 10083–1	10087	Read Online	
ACCESS	III Metrics & More		E Article Recommendations	s Supporting Information

ABSTRACT: Guanidine prenylation is an outstanding modification in alkaloid and peptide biosynthesis, but its enzymatic basis has remained elusive. We report the isolation of argicyclamides, a new class of cyanobactins with unique mono- and bis-prenylations on guanidine moieties, from *Microcystis aeruginosa* NIES-88. The genetic basis of argicyclamide biosynthesis was established by the heterologous expression and *in vitro* characterization of biosynthetic enzymes including AgcF, a new guanidine prenyltransferase. This study provides important insight into the biosynthesis of prenylated guanidines and offers a new toolkit for peptide modification.

vanobactins are a class of ribosomally synthesized and post-translationally modified peptides (RiPPs) produced by cyanobacteria.¹⁻³ Although their chemical structures are hypervariable in terms of amino acid sequences, cyanobactins are biosynthesized through a common pathway.^{4,5} Cyanobactins are directly encoded in the C-terminal region of the precursor peptide (IPR031036) as the core peptide. The core peptide is flanked by recognition sequences (RSs) that facilitate proper recognition from biosynthetic enzymes modifying the core peptide. The universal proteolytic step that removes the region preceding the core peptide (leader peptide) is mediated by subtilisin-like S8A protease (IPR023830) represented by PatA.^o Subsequently, a second subtilisin-like S8A protease represented by PatG removes the region following the core peptide (follower peptide) to yield head-to-tail cyclic or linear cyanobactins.^{6,7} In many cases, the core peptide undergoes divergent modification steps including heterocyclization to generate oxazol(in)e/thiazol(in)e,⁸⁻¹ methylesterification on C-terminal carboxylic acid,⁷ and forward or reverse prenylation and geranylation.¹²⁻¹⁷ The prenylation is catalyzed by ABBA-type prenyltransferases (PTases, IPR031037) that are selective for the isoprenyl donor (dimethylallyl diphosphate: DMAPP or geranyl diphosphate: GPP) and the residue that is prenylated.¹²⁻ On the other hand, they exhibit extremely relaxed specificity against the remainder of the prenyl acceptor, and thus cyanobactin PTases could be versatile biochemical tools for late-stage peptide modifications.^{12,18} The catalytic variations of cyanobactin PTases revealed that the residues prenylated by these PTases are not only Tyr, Ser, Thr, and Trp¹²⁻¹⁷ but also N- and C-termini of linear cyanobactins.^{7,19} However, the prenylation sites are limited to these residues, and the prenylation of a charged side chain has not been observed.

During the course of our efforts toward the discovery of natural products, by targeting cyanobacteria from the NIES collection, we found the unreported compounds 1-3 from the well-studied strain *M. aeruginosa* NIES-88, a producer of

micropeptins and kawaguchipeptins (4, 5) (Figure 1).²⁰⁻²² The LCMS profile of compounds 1-3 showed molecular ion peaks at m/z 1058, 990, and 922, respectively (Figure S1). This is reminiscent of a homologous series that differs by 68 atomic mass units, and this difference corresponds to a prenyl group. The HRESI(+)MS analysis of purified 1 yielded a molecular ion $[M + H]^+$ at m/z 1058.7128, indicative of the molecular formula $C_{57}H_{91}N_{11}O_8$ ($\Delta 0.3$ mDa). The ¹H and ¹³C NMR spectra of 1 in CD₃OD (Table S1) showed eight signals for the C α methines of α -amino acids ($\delta_{\rm C}$ 66.5, 63.5, 62.4, 61.1, 59.8, 58.4, 57.2, 51.7; $\delta_{\rm H}$ 4.66, 4.55, 4.24, 4.23, 4.23, 4.09, 3.78, 2.99), and six signals for amide NH protons (Figure S37), probably due to slow exchange to deuterium through interresidual hydrogen bonding. In addition, signals for an N-prenyl unit were also observed, and two sets of them are overlapped according to the integral intensity ($\delta_{\rm C}$ 138.6, 119.8, 40.7, 25.8, 18.1; $\delta_{\rm H}$ 5.22, 3.82, 1.76, 1.71). A detailed analysis of the 2D NMR data established that 1 is the octapeptide composed of Phe, Ile, Val (\times 2), Leu, Pro (\times 2), and Arg residues (Figure 2). The sequence of these residues was determined by interpretations of the HMBC and ROESY spectra in CD₃OD, which allowed the assignment of two partial structures: the dipeptide Arg-Val(1) and the hexapeptide Phe-Ile-Val(2)-Leu-Pro(1)-Pro(2) (Figure 2a). It was difficult to connect these two fragments, due to the overlapped signals for the α -methine protons of Arg and Val(1) at $\delta_{\rm H}$ 4.23 in CD_3OD (Figure 2a). These two fragments were connected based on the ROESY correlations in DMSO-d₆ (Figure 2b), which allowed us to close the linear fragments into a head-to-

Received: June 4, 2021 **Published:** June 28, 2021



Communication



pubs.acs.org/JACS




Figure 1. Structures of cyanobactins from M. aeruginosa NIES-88. Argicyclamides A-C (1-3) are newly reported in this study.




Figure 2. Key 2D NMR correlations of **1** in CD₃OD (a) and DMSO- d_6 (b).

tail cyclic octapeptide. The two prenyl units are attached to the two $N^{\omega}s$ of guanidine in Arg, as deduced from the DQF ¹H–¹H COSY (in DMSO- d_6) correlations between $N^{\omega}H$ (δ_H 7.42) and CH₂ (δ_H 3.75), and $N^{\delta}H$ (δ_H 7.37) and CH₂ (δ_H 3.11), as well as the HMBC correlation between C^{ω} and CH₂ (δ_H 3.75) (Figure 2b). The symmetrical pattern of bisprenylation on N^{ω} agrees with the overlapped signals of two prenyl groups, thus excluding the possibility of an N^{ω} , N^{δ} -asymmetric bis-prenylated guanidine. The amide bond between two Pro residues was assigned to be *cis* conformation based on ROESY correlations and diagnostic carbon chemical shifts ($\Delta \delta_{C\beta} - \delta_{C\gamma}$).²³

Compounds 2 and 3 have the molecular formulas of $C_{52}H_{83}N_{11}O_8$ (Δ -0.4 mDa) with $[M + H]^+$ at m/z 990.6495, and $C_{47}H_{75}N_{11}O_8$ (Δ 0.0 mDa) with $[M + H]^+$ at m/z 922.5873, respectively. Detailed analysis of the 2D NMR spectra revealed that 2 and 3 possess the same macrocyclic scaffold as 1, except that 2 has only one prenyl unit at Arg, while 3 lacks prenylation at Arg (Figure S2, Table S2). The

Marfey's analysis of 3 confirmed that the macrocyclic scaffold exclusively consists of L-amino acids (Figure S3). The structure of the cyclic scaffold was further confirmed by total synthesis of 3, using conventional solid phase peptide synthesis, followed by ring closure with a coupling reagent (Figure S4).^{24–26} While 1–3 were not cytotoxic, 1 inhibited growth of *Staphylococcus aureus*, methicillin-resistant *S. aureus* and *Bacillus subtilis* with MIC of 3.12–6.25 μ M. Notably, as the number of prenyl groups increases from one to two, the antimicrobial activity was significantly enhanced (Table S3, Figures S5–S10).

The unique N-prenylation of 1 prompted us to investigate its biosynthetic mechanism. As the cyclic scaffolds of argicyclamides exclusively consist of L-amino acids, we hypothesized that these are ribosomally synthesized peptides. Based on this assumption, we searched for a putative precursor peptide of argicyclamides in the genome of M. aeruginosa NIES-88 by tBLASTn with their possible peptide backbone sequence (RVFIVLPP) as a query; however, the corresponding gene was not found in the public genome data. Therefore, we resequenced M. aeruginosa NIES-88 by using both long and short read sequencers. De novo hybrid assembly generated a complete sequence of a 5.5 Mb chromosome and two additional small plasmids. Scanning the whole genome sequence identified two copies of putative precursor peptide genes of argicyclamide, agcE1 and agcE2, which are encoded in the remote genetic loci (Figure 3a, Figures S11 and S12). While no cyanobactin-related genes were encoded in the flanking region of *agcE1*, a putative enzyme AgcF, which shares homology with cyanobactin PTases such as Trp C-prenyltransferase KgpF (AAid, 41%),¹⁴ Trp *N*-prenyltransferase AcyF (AAid, 41%),¹⁵ and $N\alpha$ -prenyltransferase MusF2 (AAid, 35%),¹⁹ was found in the flanking region of *agcE2*. However, although the cyclic scaffolds of argicyclamides should be constructed by a set of PatA/G-like proteases, no such proteases were encoded in the vicinity of the *agcE1* nor *agcE2*. This led us to hypothesize that AgcEs are processed by putative PatA/G-like proteases that are encoded in remote genetic loci. To search them, the complete genome of M. aeruginosa NIES-88 was analyzed with HMM-based annotation.²⁷ This validated that KgpA and KgpG, proteases in kawaguchipeptin biosynthesis, are the only PatA/G-like proteases (IPR023830) in M. aeruginosa NIES-88. Notably, we detected two sets of near-identical kawaguchipeptin biosynthetic gene clusters (kgp1 and kgp2, Figure 3a) that reside in remote loci in M. aeruginosa NIES-88 chromosome (Figures S13 and S14). Genes coding for B, E, F, G proteins are identical between kgp1 and kgp2. On the other hand, while kgpA2 encodes the full-length of PatA-like protease, the Nterminal region of kgpA1 encoding catalytic triad is truncated,

Journal of the American Chemical Society




Figure 3. Genetic basis of cyanobactin biosyntheses in *M. aeruginosa* NIES-88. (a) Cyanobactin-related genes encoded in remote genetic loci of *M. aeruginosa* NIES-88 chromosome. Genes are labeled with locus numbers. The locus tag prefix (MAN88) was omitted. Homologous genes are linked and amino acid identities are shown for each linkage. (b) Primary sequences of the precursor peptides AgcEs and KgpEs, with the core peptide (bold) and proposed recognition sequences RSII and RSIII (underlined). (c) Heterologous production of **3** in *E. coli*. Extracted ion chromatograms for m/z 922.5000 are shown.

thus KgpA1 is likely to be inactive (Figure S15). Based on these observations and the fact that the RSII (recognition sequence of PatA-lile protease) and RSIII (recognition sequence of PatG-like protease) of AgcEs are similar to those of KgpE, a kawaguchipeptin precursor peptide (Figure 3b), we hypothesized that AgcEs could be matured by KgpA2 and KgpG, proteases for kawaguchipeptin biosynthesis.

To test this hypothesis, we coexpressed the precursor peptides agcE and kgpA2/kgpG in the heterologous host *E. coli* BL21 (DE3). LC-MS analyses of the transformant's metabolites revealed the production of 3, the nonprenylated cyclic peptide (Figure 3c). Omitting kgpA2 or kgpG gene resulted in the loss of 3 production. To further access the production of 3 *in vitro*, recombinant KgpG was incubated with a synthetic AgcE-core with a follower peptide (RVFIVLPPFAEDGAE). This resulted in KgpG-dependent production of 3 (Figure S19). These results demonstrated substantial promiscuity of kawaguchipeptin proteases and suggest that these are employed for constructing the cyclic scaffolds of both argicyclamides and kawaguchipeptins, which are structurally distinct.

Next, we investigated the biosynthetic origin of the bisprenylated guanidine moiety in 1. To this end, the putative

pubs.acs.org/JACS

prenyltransferase AgcF was expressed in *E. coli* and characterized *in vitro*, using dimethylallyl diphosphate (DMAPP) as a prenyl donor and synthetic **3** as an acceptor. A time-course analysis revealed the initial generation of **2**, the monoprenylated product, followed by the accumulation of **1**, the bis-prenylated product (Figure 4a). This demonstrated that




Figure 4. In vitro characterization of AgcF and proposed biosynthetic schemes of argicyclamides (1-3) and kawaguchipeptins (4, 5). (a) AgcF catalyzed sequential prenylations to convert 3 to 1, with the intermediacy of 2. Extracted ion chromatograms for 1 (m/z 1058.5000, red), 2 (m/z 990.5000, blue), and 3 (m/z 922.5000, black) are shown. (b) KgpA2/G are shared with the *agc* and *kgp* pathways to afford distinct cyclic scaffolds (3, 5), which are tailored by specialized PTases.

AgcF catalyzes two rounds of prenylation on the guanidine moiety. This conversion is Mg^{2+} -dependent and is optimal at 37 °C, pH 8.0 (Figures S20 and S21). AgcF showed no prenylation activity on synthetic analogs of 3 with Arg substituted to Trp, Tyr, Ser, Thr, or Lys (6–10, Figure S22). No prenylation was observed for linear analogs (11 and 12, Figure S22). These results show that AgcF is highly selective for 3 as a prenyl acceptor. Next, the specificity of AgcF on the isoprenyl donor was assessed by using geranyl diphosphate (GPP) and farnesyl diphosphate (FPP). Contrary to other cyanobactin PTases that are highly selective for the isoprenyl donor, ^{12–16,28} AgcF was capable of catalyzing the monogeranylation of 3 (Figures S23 and S24), highlighting its

Journal of the American Chemical Society

unusual tolerance. FPP was not accepted as an isoprenyl donor.

To gain structural insights into AgcF catalysis, we generated a computational model of AgcF, using the crystal structure of PagF, an O-Tyr PTase in prenylagaramide biosynthesis, as the template (AAid, 42%) (Figure S25).¹³ The Mg²⁺ and diphosphate binding site, as well as the proposed catalytic residue (Glu49 in AgcF and Glu51 in PagF) that activates the prenyl acceptor, are well conserved between AgcF and PagF. The substitution of Glu49 to Ala in AgcF abolished its prenylating activity, showing the general importance of this residue in the catalysis of cyanobactin PTases (Figure S26). Stark differences between AgcF and PagF were observed in the residues forming the active site entrance, where the bulky residues in PagF are substituted with substantially smaller residues in AgcF, for example, F69/G67, H138/G133, W271/ C267, and Y292/L289, respectively (Figure S25). The enlarged active site should facilitate the accommodation of a bulky substrate and enable the sequential bis-prenylation of guanidine.

A phylogenetic analysis revealed that cyanobactin PTases form clades according to their chemoselectivities (Figure S27). Notably, AgcF composes a small but distinct clade together with its close homologues, and all share the aforementioned substitutions at the active site entrance (Figure S28). The putative Arg-containing precursor peptides encoded in the neighboring regions of AgcF-like PTases suggest the presence of a new class of cyanobactins, with a bis-prenylated Arg residue yet to be identified (Figure S29).

In this study, we discovered argicyclamides (1-3), a new group of cyanobactins with a unique bis-prenylated Arg residue. Based on the complete genome sequence and series of biochemical analyses, we proposed a unique biosynthetic route for 1-3, in which the precursor peptide is processed by distantly encoded maturation proteases participating in a distinct cyanobactin biosynthetic pathway (Figure 4b). In general, cyanobactin maturation proteases act on single or multiple precursor peptides encoded in neighboring genetic loci.^{4,5,9,16,29,30} However, to our knowledge, cyanobactin proteases processing distantly encoded precursor peptides have not been previously reported.

Notably, Pancrace et al. recently reported the first biosynthetic investigation of prenylated guanidines on aeruginoguanidines/microguanidines, a group of cytotoxic nonribosomal peptides produced by Microcystis.³¹ Although not validated experimentally, guanidine prenylation is proposed to be catalyzed by AgdJ that belongs to the decaprenyl diphosphate synthase-like family (IPR001441), which shares no sequence homology with AgcF, suggesting that several enzyme families have evolved convergently to achieve guanidine prenylation. AgcF, a newly identified PTase in this study is, to our knowledge, the first guanidine PTase with biochemical validation.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/jacs.1c05732.

Synthetic procedure, NMR, LC-MS, HPLC analysis, strains, oligonucleotides, plasmids, genome sequence, bioinformatics, biological activity assay, detailed methods, and materials (PDF)

AUTHOR INFORMATION

Corresponding Authors

pubs.acs.org/JACS

- Toshiyuki Wakimoto Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo 060-0812, Japan; [®] orcid.org/0000-0003-2917-1797; Email: wakimoto@pharm.hokudai.ac.jp
- Tatsufumi Okino Graduate School of Environmental Science and Faculty of Environmental Earth Science, Hokkaido University, Sapporo 060-0810, Japan; orcid.org/0000-0002-8363-0467; Email: okino@ ees.hokudai.ac.jp

Authors

- Chin-Soon Phan Faculty of Environmental Earth Science, Hokkaido University, Sapporo 060-0810, Japan; © orcid.org/0000-0002-6500-696X
- Kenichi Matsuda Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo 060-0812, Japan; o orcid.org/0000-0002-9269-688X
- Nandani Balloo Graduate School of Environmental Science, Hokkaido University, Sapporo 060-0810, Japan
- Kei Fujita Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

Complete contact information is available at: https://pubs.acs.org/10.1021/jacs.1c05732

Author Contributions

[#]C.-S.P. and K.M. contributed equally.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was partly supported by the Asahi Glass Foundation, the Naito Foundation, the Uehara Memorial Foundation, the Sumitomo Foundation-Grant for Basic Science Research Projects, Daiichi Sankyo Foundation of Life Science, Global Station for Biosurfaces and Drug Discovery, a project of Global Institution for Collaborative Research and Education at Hokkaido University, the Japan Agency for Medical Research and Development (AMED Grant Number JP19ae0101045), the Japan Science and Technology Agency (JST Grant Numbers ACT-X JPMJAX201F and A-STEP JPMJTR20US) and Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (JSPS KAKENHI Grant Numbers JP16703511, JP18056499, and JP19178402). C.-S.P. is a recipient of the JSPS Postdoctoral Fellowship for Foreign Researchers (ID No. P19096).

REFERENCES

(1) Arnison, P. G.; Bibb, M. J.; Bierbaum, G.; Bowers, A. A.; Bugni, T. S.; Bulaj, G.; Camarero, J. A.; Campopiano, D. J.; Challis, G. L.; Clardy, J.; Cotter, P. D.; Craik, D. J.; Dawson, M.; Dittmann, E.; Donadio, S.; Dorrestein, P. C.; Entian, K. D.; Fischbach, M. A.; Garavelli, J. S.; Göransson, U.; Gruber, C. W.; Haft, D. H.; Hemscheidt, T. K.; Hertweck, C.; Hill, C.; Horswill, A. R.; Jaspars, M.; Kelly, W. L.; Klinman, J. P.; Kuipers, O. P.; Link, A. J.; Liu, W.; Marahiel, M. A.; Mitchell, D. A.; Moll, G. N.; Moore, B. S.; Müller, R.; Nair, S. K.; Nes, I. F.; Norris, G. E.; Olivera, B. M.; Onaka, H.; Patchett, M. L.; Piel, J.; Reaney, M. J.; Rebuffat, S.; Ross, R. P.; Sahl,

Journal of the American Chemical Society

H. G.; Schmidt, E. W.; Selsted, M. E.; Severinov, K.; Shen, B.; Sivonen, K.; Smith, L.; Stein, T.; Süssmuth, R. D.; Tagg, J. R.; Tang, G. L.; Truman, A. W.; Vederas, J. C.; Walsh, C. T.; Walton, J. D.; Wenzel, S. C.; Willey, J. M.; van der Donk, W. A. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. *Nat. Prod. Rep.* **2013**, *30*, 108–160.

(2) Gu, W.; Dong, S. H.; Sarkar, S.; Nair, S. K.; Schmidt, E. W. The biochemistry and structural biology of cyanobactin pathways: enabling combinatorial biosynthesis. *Methods Enzymol.* **2018**, *604*, 113–163.

(3) Montalbán-López, M.; Scott, T. A.; Ramesh, S.; Rahman, I. R.; van Heel, A. J.; Viel, J. H.; Bandarian, V.; Dittmann, E.; Genilloud, O.; Goto, Y.; Grande Burgos, M. J.; Hill, C.; Kim, S.; Koehnke, J.; Latham, J. A.; Link, A. J.; Martínez, B.; Nair, S. K.; Nicolet, Y.; Rebuffat, S.; Sahl, H. G.; Sareen, D.; Schmidt, E. W.; Schmitt, L.; Severinov, K.; Süssmuth, R. D.; Truman, A. W.; Wang, H.; Weng, J. K.; van Wezel, G. P.; Zhang, Q.; Zhong, J.; Piel, J.; Mitchell, D. A.; Kuipers, O. P.; van der Donk, W. A. New developments in RiPP discovery, enzymology and engineering. *Nat. Prod. Rep.* **2021**, *38*, 130–239.

(4) Donia, M.; Hathaway, B.; Sudek, S.; Haygood, M. G.; Rosovitz, M. J.; Ravel, J.; Schmidt, E. W. Natural combinatorial peptide libraries in cyanobacterial symbionts of marine ascidians. *Nat. Chem. Biol.* **2006**, *2*, 729–735.

(5) Donia, M.; Ravel, J.; Schmidt, E. W. A global assembly line for cyanobactins. *Nat. Chem. Biol.* **2008**, *4*, 341–343.

(6) Lee, J.; McIntosh, J.; Hathaway, B. J.; Schmidt, E. W. Using marine natural products to discover a protease that catalyzes peptide macrocyclization of diverse substrates. *J. Am. Chem. Soc.* **2009**, *131*, 2122–2124.

(7) Sardar, D.; Hao, Y.; Lin, Z.; Morita, M.; Nair, S. K.; Schmidt, E. W. Enzymatic N- and C-protection in cyanobactin RiPP natural products. *J. Am. Chem. Soc.* **2017**, *139*, 2884–2887.

(8) McIntosh, J. A.; Schmidt, E. W. Marine molecular machines: heterocyclization in cyanobactin biosynthesis. *ChemBioChem* **2010**, *11*, 1413–1421.

(9) Schmidt, E. W.; Nelson, J. T.; Rasko, D. A.; Sudek, S.; Eisen, J. A.; Haygood, M. G.; Ravel, J. Patellamide A and C biosynthesis by a microcin-like pathway in *Prochloron didemni*, the cyanobacterial symbiont of *Lissoclinum patella*. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, 102, 7315–7320.

(10) Houssen, W. E.; Bent, A. F.; McEwan, A. R.; Pieiller, N.; Tabudravu, J.; Koehnke, J.; Mann, G.; Adaba, R. I.; Thomas, L.; Hawas, U. W.; Liu, H.; Schwarz-Linek, U.; Smith, M. C.; Naismith, J. H.; Jaspars, M. An efficient method for the in vitro production of azol(in)e-based cyclic peptides. *Angew. Chem., Int. Ed.* **2014**, *53*, 14171–14714.

(11) Gao, S.; Ge, Y.; Bent, A. F.; Schwarz-Linek, U.; Naismith, J. H. Oxidation of the cyanobactin precursor peptide is independent of the leader peptide and operates in a defined order. *Biochemistry* **2018**, *57*, 5996–6002.

(12) McIntosh, J. A.; Donia, M. S.; Nair, S. K.; Schmidt, E. W. Enzymatic basis of ribosomal peptide prenylation in cyanobacteria. *J. Am. Chem. Soc.* **2011**, *133*, 13698–13705.

(13) Hao, Y.; Pierce, E.; Roe, D.; Morita, M.; McIntosh, J. A.; Agarwal, V.; Cheatham, T. E.; Schmidt, E. W.; Nair, S. K. Molecular basis for the broad substrate selectivity of a peptide prenyltransferase. *Proc. Natl. Acad. Sci. U. S. A.* **2016**, *113*, 14037–14042.

(14) Parajuli, A.; Kwak, D. H.; Dalponte, L.; Leikoski, N.; Galica, T.; Umeobika, U.; Trembleau, L.; Bent, A.; Sivonen, K.; Wahlsten, M.; Wang, H.; Rizzi, E.; De Bellis, G.; Naismith, J.; Jaspars, M.; Liu, X.; Houssen, W.; Fewer, D. P. A unique tryptophan C-prenyltransferase from the kawaguchipeptin biosynthetic pathway. *Angew. Chem., Int. Ed.* **2016**, *55*, 3596–3599.

(15) Dalponte, L.; Parajuli, A.; Younger, E.; Mattila, A.; Jokela, J.; Wahlsten, M.; Leikoski, N.; Sivonen, K.; Jarmusch, S. A.; Houssen, W. E.; Fewer, D. P. *Biochemistry* **2018**, *57*, 6860–6867. (16) Morita, M.; Hao, Y.; Jokela, J. K.; Sardar, D.; Lin, Z.; Sivonen, K.; Nair, S. K.; Schmidt, E. W. N-Prenylation of tryptophan by an aromatic prenyltransferase from the cyanobactin biosynthetic pathway. *J. Am. Chem. Soc.* **2018**, *140*, 6044–6048.

(17) Purushothaman, M.; Sarkar, S.; Morita, M.; Gugger, M.; Schmidt, E. W.; Morinaka, B. I. Genome-mining-based discovery of the cyclic peptide tolypamide and TolF, a Ser/Thr forward Oprenyltransferase. *Angew. Chem., Int. Ed.* **2021**, *60*, 8460–8465.

(18) Sarkar, S.; Gu, W.; Schmidt, E. W. Expanding the chemical space of synthetic cyclic peptides using a promiscuous macrocyclase from prenylagaramide biosynthesis. *ACS Catal.* **2020**, *10*, 7146–7153.

(19) Mattila, A.; Andsten, R.-M.; Jumppanen, M.; Assante, M.; Jokela, J.; Wahlsten, M.; Mikula, K. M.; Sigindere, C.; Kwak, D. H.; Gugger, M.; Koskela, H.; Sivonen, K.; Liu, X.; Yli-Kauhaluoma, J.; Iwaï, H.; Fewer, D. P. Biosynthesis of the bis-prenylated alkaloids muscoride A and B. ACS Chem. Biol. **2019**, *14*, 2683–2690.

(20) Ishida, K.; Matsuda, H.; Murakami, M.; Yamaguchi, K. Kawaguchipeptin A, a novel cyclic undecapeptide from cyanobacterium *Microcystis aeruginosa* (NIES-88). *Tetrahedron* **1996**, *52*, 9025–9030.

(21) Ishida, K.; Matsuda, H.; Murakami, M.; Yamaguchi, K. Kawaguchipeptin B, an antibacterial cyclic undecapeptide from the cyanobacterium *Microcystis aeruginosa*. J. Nat. Prod. **1997**, 60, 724–726.

(22) Ishida, K.; Matsuda, H.; Murakami, M. Micropeptins 88-A to 88-F, chymotrypsin inhibitors from the cyanobacterium *Microcystis aeruginosa* (NIES-88). *Tetrahedron* **1998**, *54*, 5545–5556.

(23) Kwon, O.-S.; Kim, C.-K.; Byun, W. S.; Oh, J.; Lee, Y.-J.; Lee, H.-S.; Sim, C. J.; Oh, D.-C.; Lee, S. K.; Oh, K.-B.; Shin, J. Cyclopeptides from the sponge *Stylissa flabelliformis. J. Nat. Prod.* **2018**, *81*, 1426–1434.

(24) Subirós-Funosas, R.; Prohens, R.; Barbas, R.; El-Faham, A.; Albericio, F. Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. *Chem. - Eur. J.* **2009**, *15*, 9394–9403.

(25) Coste, J.; Le-Nguyen, D.; Castro, B. PyBOP®: A new peptide coupling reagent devoid of toxic by-product. *Tetrahedron Lett.* **1990**, 31, 205–208.

(26) Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
(27) Tanizawa, Y.; Fujisawa, T.; Nakamura, Y. DFAST: a flexible

prokaryotic genome annotation pipeline for faster genome publication. *Bioinformatics* **2018**, *34*, 1037–1039.

(28) Estrada, P.; Morita, M.; Hao, Y.; Schmidt, E. W.; Nair, S. K. A Single amino acid switch alters the isoprene donor specificity in ribosomally synthesized and post-translationally modified peptide prenyltransferases. J. Am. Chem. Soc. **2018**, 140, 8124–8127.

(29) Donia, M. S.; Schmidt, E. W. Linking chemistry and genetics in the growing cyanobactin natural products family. *Chem. Biol.* 2011, 18, 508–519.

(30) Leikoski, N.; Fewer, D. P.; Jokela, J.; Alakoski, P.; Wahlsten, M.; Sivonen, K. Analysis of an inactive cyanobactin biosynthetic gene cluster leads to discovery of new natural products from strains of the genus *Microcystis*. *PLoS One* **2012**, *7*, e43002.

(31) Pancrace, C.; Ishida, K.; Briand, E.; Pichi, D. G.; Weiz, A. R.; Guljamow, A.; Scalvenzi, T.; Sassoon, N.; Hertweck, C.; Dittmann, E.; Gugger, M. Unique biosynthetic pathway in bloom-forming cyanobacterial genus *Microcystis* jointly assembles cytotoxic aeruginoguanidines and microguanidines. *ACS Chem. Biol.* **2019**, *14*, 67–75.

NOTE ADDED AFTER ASAP PUBLICATION

This paper was published on June 28, 2021. Figure 4 has been updated and the paper was re-posted on June 29, 2021.